Stifel Maintains Buy on Arrowhead Pharma, Lowers Price Target to $96
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Stifel analyst James Condulis maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price target from $104 to $96.
Stifel analyst James Condulis maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price target from $104 to $96.
